Royal Bank of Canada Raises Holdings in DENTSPLY SIRONA Inc. $XRAY

Royal Bank of Canada boosted its position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 137.7% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 256,701 shares of the medical instruments supplier’s stock after purchasing an additional 148,702 shares during the quarter. Royal Bank of Canada owned about 0.13% of DENTSPLY SIRONA worth $2,978,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in XRAY. First Eagle Investment Management LLC raised its position in shares of DENTSPLY SIRONA by 3.2% in the fourth quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock valued at $167,342,000 after buying an additional 458,744 shares during the last quarter. AQR Capital Management LLC boosted its position in DENTSPLY SIRONA by 109.8% during the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after acquiring an additional 6,970,086 shares during the last quarter. Lazard Asset Management LLC grew its stake in DENTSPLY SIRONA by 0.9% during the 3rd quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock valued at $129,445,000 after acquiring an additional 92,868 shares in the last quarter. Southpoint Capital Advisors LP purchased a new stake in DENTSPLY SIRONA during the 1st quarter valued at about $116,000,000. Finally, Armistice Capital LLC raised its holdings in DENTSPLY SIRONA by 27.2% in the 4th quarter. Armistice Capital LLC now owns 7,298,000 shares of the medical instruments supplier’s stock valued at $83,416,000 after acquiring an additional 1,562,000 shares during the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

Insiders Place Their Bets

In other DENTSPLY SIRONA news, Director Brian P. Mckeon purchased 10,000 shares of the firm’s stock in a transaction dated Friday, June 12th. The shares were acquired at an average price of $10.12 per share, with a total value of $101,200.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at approximately $101,200. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Michael J. Barber purchased 15,175 shares of the stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $9.88 per share, with a total value of $149,929.00. Following the completion of the acquisition, the director owned 55,943 shares in the company, valued at approximately $552,716.84. This trade represents a 37.22% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 35,160 shares of company stock valued at $351,179 over the last quarter. 0.46% of the stock is owned by insiders.

DENTSPLY SIRONA Stock Performance

DENTSPLY SIRONA stock opened at $11.59 on Friday. The firm has a 50 day simple moving average of $11.94 and a 200-day simple moving average of $11.86. DENTSPLY SIRONA Inc. has a 1-year low of $9.40 and a 1-year high of $14.86. The company has a debt-to-equity ratio of 1.48, a current ratio of 1.63 and a quick ratio of 1.07. The stock has a market cap of $2.31 billion, a price-to-earnings ratio of -4.21, a price-to-earnings-growth ratio of 1.38 and a beta of 0.85.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.35 by $0.17. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The business had revenue of $898.00 million during the quarter, compared to the consensus estimate of $889.93 million. During the same quarter last year, the firm earned $0.52 EPS. The business’s revenue was down 4.1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, analysts expect that DENTSPLY SIRONA Inc. will post 1.49 EPS for the current year.

Analysts Set New Price Targets

XRAY has been the topic of several recent research reports. Piper Sandler boosted their target price on DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Wednesday, July 29th. Mizuho cut their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. UBS Group reduced their price objective on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Barrington Research set a $15.00 price objective on DENTSPLY SIRONA in a research note on Monday, August 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research note on Monday, August 3rd. Three research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $13.38.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.